Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer

In this trial, all the patients will have weekly paclitaxel and cisplatin as neoadjuvant chemotherapy for 4 cycles. Patients with Her2 positive tumor will also receive the trastuzumab.

Inclusion criteria

• Women aged ≥18years and ≤70 years
• At least on measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size ≥2 cm, T2-4 N0-2M0
• ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR positive is defined as >1% stained cells and HER2-positive is defined as immuno-histochemistry (IHC) 3+ or FISH ratio ≥ 2.0
• No prior systemic or loco-regional treatment of breast cancer
• ECOG 0-2
• Adequate bone marrow function:WBC≥4.0×109/L, Absolute neutrophil count（ANC）≥1.5×109/L, Platelets（PLT）≥100×109/L, Hemoglobin（Hb）≥90g/L;aspartate aminotransferase(AST),Alanine aminotransferase (ALT)≤1.5 upper normal limit （UNL）, creatinine≤1.5 UNL, bilirubin≤1.5UNL
• No obvious main organs dysfunction

Exclusion criteria

• Unwilling or unable to use an acceptable method of contraception in 8 weeks (including 8 weeks) after final dose of test drug
• Patient is pregnant or breast feeding
• Inflammatory breast cancer and metastatic breast cancer
• Any evidence of sense or motor nerve disorders
• Patients with medical conditions taht indicate intolerant to neoadjuvant therapy, including uncontrolled cardiovascular disease, severe infection
• Any concurrent malignancy other than breast cancer
• Know severe hypersensitivity to any drugs in this study